T[he]{.smallcaps} activation of the cdks is a central issue of cell cycle regulation. From S phase, cyclin B accumulates and binds to p34^cdc2^. Upon binding to cyclin B, p34^cdc2^ is phosphorylated on Thr-161, a site essential for the catalytic activity of p34^cdc2^. Simultaneously, p34^cdc2^ is phosphorylated on Thr-14 and Tyr-15 to prevent the premature activation of p34^cdc2^/cyclin B (for review see by [@B6]). The phosphorylation of Thr-161 is carried out by cyclin-dependent kinase (CDK)^1^-activating kinase (CAK; [@B56]; [@B58], [@B59]; [@B8]; [@B49]), and the phosphorylation at Thr-14 and Tyr-15 is performed by both Wee1/Mik1 ([@B9]; [@B46]; [@B28]; [@B36]) and Myt1 kinases ([@B37]). *Xenopus* Cdc25, a dual-specificity phosphatase, dephosphorylates both Thr-14 and Tyr-15 ([@B20]; [@B22]). During S phase, the activity of Thr-14 and Tyr-15 kinase is held high, and the activity of Cdc25 is low. When DNA replication is completed, the balance between Thr-14 and Tyr-15 kinase and Cdc25 phosphatase is switched to activate p34^cdc2^/cyclin B. In mammalian cells, Cdc25 is comprised of Cdc25A, Cdc25B, and Cdc25C ([@B50]; [@B12]; [@B38]; [@B32]). All three Cdc25 species are functional homologues of the *Schizosaccharomyces pombe cdc25* ^+^ gene. Cdc25A is expressed in late G~1~ and has been reported to be required for initiation of S phase ([@B21]), whereas the role of Cdc25B in the cell cycle remains vague. It is thought to be required for mitosis ([@B12]; [@B38]; [@B18]) and for development of human cancer ([@B13]). On the other hand, Cdc25C, which is phosphorylated and thereby activated by p34^cdc2^/cyclin B, induces the full activation of p34^cdc2^ by forming a positive feedback mutual activation loop ([@B22]; [@B16]; [@B19]). A trigger for a full activation of p34^cdc2^/cyclin B that initiates mitosis is unknown. It is supposed to be carried out by the balance between cyclin and PP2A ([@B57]; [@B26], [@B27]). PP2A inhibits Thr-161 phosphorylation ([@B27]), and the increment of cyclin accumulates the p34^cdc2^/cyclin B complexes, which titrates out the stoichiometric inhibitors of the p34^cdc2^/cyclin B complex ([@B23]; [@B25]). Recently, Cdc25C has been found to be phosphorylated and thereby activated by Plx1 POLO-like kinase ([@B24]). Wee1 tyrosine kinase is inactivated by Nim1 serine/threonine kinase in *S. pombe* ([@B63]). Nim1p is localized within the cytoplasm and Wee1p within the nucleus ([@B62]). Similarly, in BHK21 cells, Cdc25C is localized within the cytoplasm and Wee1p within the nucleus ([@B14]). In HeLa cells, cyclin B has been reported to be localized within the cytoplasm ([@B47], [@B48]). To initiate mitosis, therefore, Nim1p, Cdc25C, and cyclin B are supposed to enter the nucleus. Thus, in addition to protein phosphorylation, the cellular compartment is thought to play a role in the cell cycle regulation.

In hamster BHK21 cells arrested in S phase, p34^cdc2^/cyclin B is prematurely activated, and cells enter mitosis either by temperature-sensitive (ts) BN2 mutation of BHK21 cell line or by the administration of caffeine, resulting in premature chromatin condensation (PCC; [@B40]; [@B55]). In both cases, protein synthesis inhibitors block PCC induction ([@B41]; [@B55]; [@B42]). These findings have been considered to indicate that a new synthesis of proteins is required for the activation of p34^cdc2^/cyclin B. [@B61] originally found that protein synthesis inhibitors block the *Xenopus* oocyte maturation induced by progesterone. As a protein that is newly synthesized by progesterone treatment, cyclin B was plausible, since it is synthesized from S phase onwards and is essential for p34^cdc2^/cyclin B activation ([@B7]). However, cyclin B already exists in *Xenopus* oocytes ([@B33]) and also in BHK21 cells arrested in S phase ([@B42]). Another candidate for a newly synthesized activator is a c-mos proto-oncogene product (MOS)-like protein. In *Xenopus* oocyte, MOS that is synthesized just before meiosis I is essential for the activation of p34^cdc2^/cyclin B ([@B51]). Microinjected MOS protein can induce meiosis I, but not meiosis II, without protein synthesis ([@B64]; [@B11]). Thus, the synthesis of protein(s) other than MOS appears to be required to complete *Xenopus* oocyte maturation. Alternatively, if *Xenopus* oocytes and BHK21 cells arrested in S phase contain all the molecules required for p34^cdc2^/cyclin B activation, the inhibition of p34^cdc2^/cyclin B activation caused by blocking protein synthesis may reflect the loss of endogenous activators of p34^cdc2^/cyclin B that are rapidly turning over.

tsBN2 mutation causes the loss of RCC1 function, resulting in either G~1~ arrest or premature activation of p34^cdc2^/cyclin B depending on the cell cycle stage ([@B40]; [@B42]). RCC1 is localized on chromatin ([@B10]) and functions as a GDP/GTP exchanging factor on Ran, a Ras-like nuclear G protein ([@B2]). GTP hydrolysis of Ran is essential for the nuclear import of karyophilic proteins ([@B31]; [@B35]). It can be argued, therefore, that all of the phenotypes of *rcc1^−^* are indirect consequences of the role of Ran in nuclear transport. However, PCC induced by the loss of RCC1 can be inhibited by microinjection of both GTP- and GTPγS-bound Ran ([@B45]), indicating that GTP-Ran plays some role in the nucleus. This finding is consistent with the fact that Yrb2p that possesses a Ran-binding domain similar to RanBP1/Yrb1p ([@B5]), thereby specifically binding to the GTP-bound Gsp1p *S. cerevisiae* Ran homologue, is localized in the nucleus ([@B43]). The disruptant of the *YRB2* gene, which is cold sensitive, has no defect in the nucleus/cytosol exchange of macromolecules ([@B43]).

When tsBN2 cells are incubated in S phase at 40°C, the nonpermissive temperature, Cdc25C enters the nucleus parallel with PCC induction ([@B53]). This is inconsistent with the findings that the loss of RCC1 function retards nuclear protein import ([@B60]; [@B4]). We noticed the fact that the inhibition of protein synthesis blocks the nuclear import of Cdc25C as well as the activation of p34^cdc2^/cyclin B ([@B53]), which suggests that loss of RCC1 function induces a new protein synthesis required either for nuclear entrance of Cdc25C or for the activation of p34^cdc2^/cyclin B. To clarify the relationship between the loss of RCC1 and the p34^cdc2^/cyclin B activation, we began to identify the protein(s) required for p34^cdc2^/cyclin B activation induced by loss of RCC1 ([@B42]). To do this, we have first established a method to activate the p34^cdc2^/ cyclin B complexes in vitro by using the extract prepared from BHK21 cells arrested in S phase ([@B53]). In this paper, we confirmed our previous results by using tsBN2 cells. We found that the in vitro activation of p34^cdc2^/cyclin B occurred without new protein synthesis and that p34^cdc2^/cyclin B was not activated in the extract of cells pretreated with protein synthesis inhibitor. Instead of a new synthesis of p34^cdc2^/cyclin B activators, therefore, an endogenous activator(s) of p34^cdc2^/cyclin B was suggested to be lost by blocking protein synthesis. Cdc25B, but not Cdc25C or Cdc25A, was identified as such an unstable activator of p34^cdc2^/cyclin B.

Materials and Methods
=====================

Cells and Cell Culture
----------------------

The BHK21 cell line derived from golden hamsters and its ts mutant tsBN2 cell line ([@B40]) and human HeLa cell line were grown in DME containing 10% calf or FCS in a humidified atmosphere containing 10% CO~2~. HeLa cells were cultured at 37.5°C, and BHK21 and tsBN2 cells were cultured at 33.5°C. As the nonpermissive temperature, 40°C was used for tsBN2 cells.

Synchronization of Cells
------------------------

Wild-type BHK21 and tsBN2 cells were cultured in isoleucine-free medium for 24--30 h (G~0~/G~1~ arrest) and then in DME containing 10% FCS and 2.5 mM hydroxyurea (HU) for 15.5 h (S phase arrest) as described ([@B42]). To synchronize in mitosis, after the release from HU block, cells were incubated in DME medium containing 10% FCS and 0.4 μg/ml Nocodazole for 8 h.

HeLa cells were cultured in medium containing thymidine (2 mM) for 14 h, in a normal growth medium for 13 h, and finally in medium containing 2.5 mM HU for 14 h (S phase arrest).

Preparation of Cell Extracts
----------------------------

Cells were collected with a scraper and then sequentially washed, first with TD buffer containing 136.8 mM NaCl, 5 mM KCl, 0.7 mM Na~2~HPO~4~, and 25 mM Tris-HCl (pH 7.4), with the EB buffer, and finally with the 0.5 × EB buffer as described ([@B53]). The EB buffer contained 20 mM Hepes-KOH (pH 7.4), 50 mM KCl, 50 mM 2-glycerophosphate, 15 mM EGTA, and 10 mM MgCl~2~. Washed cells were lysed by pipetting and vortexing in the buffer (0.5 × EB-1), 0.5 × EB buffer supplemented with 5 μg/ml cytochalasin B, 5 mM DTT, a mixture of protease inhibitors, 1 mM ATP-γ-S, and 0.5% NP-40. After being kept on ice for 30 min, the extract was centrifuged at 2,000 *g* for 5 min. The supernatant was further centrifuged at 80,000 *g* for 30 min. The resulting supernatant was used as the cytosolic extracts. The total cell extract was prepared with the same procedure, except that the cells were lysed directly in the 0.5 × EB-1 buffer supplemented with 500 mM NaCl. The mixture of protease inhibitors contained 2 μg/ml of aprotinin, antipain dihydrochloride, leupeptin, and pepstatin A, and 100 μM *p*-amidinophenyl methansulfonyl fluoride (*p*APMSF).

The cell extracts were desalted, concentrated by centricon (Amicon Corp., Danvers, MA), and then subjected to use as the cell extracts for the in vitro activation assay of p34^cdc2^ protein kinase.

Preparation of E. coli-Produced Hamster Cdc25C
----------------------------------------------

*E. coli* BL21 (DE3)LysS/pGEX-KG-hamster Cdc25C (a gift of K. Yamashita, Kyushu University, Fukuoka, Japan) strains were cultured at 30°C up to an OD 600 of 0.4, treated with IPTG (final concentration, 1.0 mM) for 3 h, and then collected by centrifugation. Cell-pellet was lysed and glutathione-S-transferase (GST)-Cdc25C was purified using glutathione Sepharose 4B beads (Pharmacia Fine Chemicals, Piscataway, NJ) as described previously ([@B43]). Eluted GST-Cdc25C was further purified by gel filtration using Sephacryl S-100 HR column (Pharmacia Fine Chemicals).

Immunodepletion of cyclin B, cdc25B, and cdc25C from Cytoplasmic Extract
------------------------------------------------------------------------

The antibody was mixed with protein G Sepharose (Pharmacia Fine Chemicals), rotated at 4°C for 2 h. Beads were pulled down by centrifugation, washed with 0.5 × EB-1 buffer, and then suspended in the cytosolic extracts. After rotation for 2 h at 4°C, the beads were pulled down by centrifugation. The resulting supernatant was used as immunodepleted extracts.

In Vitro Activation of p34^cdc2^ Histone H1 Kinase and Assay of Histone H1 Kinase Activity
------------------------------------------------------------------------------------------

The extract of 5--15 μl (protein concentration: 3 mg/ml) was incubated at 30°C in the presence of 1 mM ATP, 10 mM creatine phosphate, and 2.5 μg/ml creatine kinase as an energy source ([@B22]). The reaction was stopped by a buffer containing 40 mM Hepes-NaOH (pH 7.5), 60 mM 2-glycerophosphate, 20 mM *p*-nitrophenyl phosphate, 0.5 mM Na~3~VO~4~, 250 mM NaCl, 15 mM MgCl~2~, 1% Triton X-100, 1 mM DTT, and a mixture of protease inhibitors. p34^cdc2^/cyclin B complexes were precipitated with the anti-cyclin B1 antibody or the p13^suc1^ beads ([@B42]), as indicated. The histone H1 kinase activity of precipitates was assayed by using the histone H1 as the substrate, as described ([@B42]).

The reaction was carried out more than twice by using different extracts.

Immunoblotting
--------------

Antibodies used were the anti-cdc2 antibodies against PSTAIR peptide ([@B42]), the anti-phosphotyrosine antibody, pTyr (a gift of Dr. J.Y.J. Wang, University of California, San Diego, CA; [@B34]), and the antibodies against cdc25A, cdc25B and cdc25C antibodies ([@B53]), cyclin B, and cdk2 (all from Santa Cruz Biotechnology, Santa Cruz, CA). The procedure for immunoblotting was carried out as described elsewhere (Nishitani et al., 1990), except that the detection was achieved using an ECL detection system (Amersham).

Pulse--Chase of Cdc25B
----------------------

Cells were preincubated in methionine-free medium for 1 h and then labeled with 100 μCi/ml of \[^35^S\][l]{.smallcaps}-methionine (ICN Biochemicals Inc., Irvine, CA) for 3 h. After washing out the labeled medium, cells were given the medium containing ten times the concentration (2 mM) of methionine. Cdc25B was immunoprecipitated using the anti-Cdc25B antibody, electrophoresed in SDS--10% polyacrylamide gel, and analyzed by autoradiography.

Transient Over-Expression of Cdc25B
-----------------------------------

Wild-type BHK21 cells were seeded, and after 18 to 23 h of incubation at 33.5°C, cells were transfected with plasmid pcD2-human Cdc25B (a gift from H. Okayama, Tokyo University, Tokyo, Japan) using lipofection (Lipofectamin^TM^; GIBCO BRL, Gaithersburg, MD) as described previously ([@B30]).

Results
=======

In Vitro Activation of p34^cdc2^/cyclin B
-----------------------------------------

A series of cultures of tsBN2 cells arrested in S phase (throughout this paper, cells were arrested in S phase except for the case mentioned) was incubated at 40°C, the nonpermissive temperature. Every hour, cells were harvested and lysed. From the total cell extracts prepared, p34^cdc2^/cyclin B complexes were precipitated with p13^suc1^ beads and assayed for histone H1 kinase activity as described in Materials and Methods. As previously reported ([@B42]), the histone H1 kinase activity of p34^cdc2^/cyclin B increased by incubating tsBN2 cells at 40°C (Fig. [1](#F1){ref-type="fig"} *A*). When the same extracts were incubated in vitro at 30°C, the histone H1 kinase activity of p34^cdc2^/cyclin B was also increased (Fig. [1](#F1){ref-type="fig"} *B*). Such an in vitro activation of p34^cdc2^/cyclin B occurred in the extract of tsBN2 cells prepared before increasing the temperature (Fig. [1](#F1){ref-type="fig"} *A*, 0 h), as well as in the extract of tsBN2 cells that had been incubated at 40°C for 1 h and had no histone H1 kinase activity yet (Fig. [1](#F1){ref-type="fig"} *A*, 1 h). The finding that p34^cdc2^/cyclin B was activated in the cell extracts prepared from tsBN2 cells that had been harvested before increasing the temperature indicated that the disruption of cells, rather than the mutation of tsBN2 cells, induced an in vitro activation of p34^cdc2^/cyclin B. To address this issue, the extract was prepared from wild-type BHK21 cells and incubated at 30°C for 1 h. To specifically detect the activity of p34^cdc2^/cyclin B complex, we used, henceforth, the anti-cyclin B antibody instead of p13^suc1^ beads. The p34^cdc2^/cyclin B was activated in the extract of wild-type BHK21 cells (Fig. [2](#F2){ref-type="fig"}, columns *3* and *4*) as reported ([@B53]).

In parallel with the activation of p34^cdc2^/cyclin B, the molecular mass of p34^cdc2^ was reduced, as reported ([@B1]), consistent with the dephosphorylation of Tyr-15 of p34^cdc2^, which was confirmed by using the anti-pTyr antibody that specifically recognizes phosphorylated tyrosine ([@B34]) (Fig. [3](#F3){ref-type="fig"}).

Protein Synthesis Required for Activation of p34^cdc2^/cyclin B
---------------------------------------------------------------

In the presence of protein synthesis inhibitor, while RCC1 disappears due to the mutation, the activation of p34^cdc2^/ cyclin B does not occur in tsBN2 cells arrested in S phase, at 40°C, the nonpermissive temperature ([@B41]; [@B42]). To investigate the effect of protein synthesis inhibitor on the activation of p34^cdc2^/cyclin B, we prepared the extracts from S phase-arrested wild-type BHK21 cells that had been incubated in the presence of protein synthesis inhibitor cycloheximide (10 μg/ml) for 1 h before cell harvest (henceforth designated cycloheximide treated). When the extract of cycloheximide-treated cells was incubated at 30°C for 1 h, there was no activation of p34^cdc2^/cyclin B (Fig. [2](#F2){ref-type="fig"}, columns *1* and *2*), consistent with the finding that p34^cdc2^ was not dephosphorylated (Fig. [3](#F3){ref-type="fig"}, lanes *1* and *2*). Therefore, cycloheximide-treated cells had no ability to activate the p34^cdc2^/cyclin B complexes, both in vivo and in vitro.

To exclude the possibility that cycloheximide carried over from cycloheximide-treated cells inhibited the activation of p34^cdc2^/cyclin B, the extract was prepared from wild-type BHK21 cells that had not been treated with cycloheximide, and then incubated in vitro either in the presence or absence of 10 μg/ml of cycloheximide. In both cases, p34^cdc2^/cyclin B was activated (Fig. [2](#F2){ref-type="fig"}, compare columns *4* and *6*), indicating that BHK21 cells that were arrested in S phase possessed all molecules required for the observed in vitro activation of p34^cdc2^/cyclin B. The lack of activation of p34^cdc2^/cyclin B in the extract prepared from cycloheximide-treated cells, therefore, suggested that some molecules or protein modifications required for the activation of p34^cdc2^/cyclin B were lost during the blocking of protein synthesis.

Activator(s), but Not Inhibitor(s) of p34^cdc2^/cyclin B Was Lost by Blocking Protein Synthesis
-----------------------------------------------------------------------------------------------

To investigate the possibility that the activator(s) of p34^cdc2^/cyclin B was lost by blocking protein synthesis, the extract was prepared from S phase-arrested BHK21 cells that had been either treated with cycloheximide or not treated with cycloheximide (henceforce designated nontreated) as described in Materials and Methods. To exclude the possibility that p34^cdc2^/cyclin B is involved in the activation step, the p34^cdc2^/cyclin B complexes were depleted using the anti-cyclin B antibodies, from these extracts. The cyclin B-depleted extracts were then mixed and incubated at 30°C, with the extract prepared either from cycloheximide-treated or from nontreated cells, respectively.

The cyclin B-depleted extract prepared from nontreated cells, while it had no activity of p34^cdc2^/cyclin B (Fig. [4](#F4){ref-type="fig"} *C*), possessed the ability to activate the p34^cdc2^/cyclin B within the extract prepared from cycloheximide-treated cells (Fig. [4](#F4){ref-type="fig"} *A*). On the other hand, the cyclin B-depleted extract prepared from cycloheximide-treated cells had no ability to activate the p34^cdc2^/cyclin B within the extract prepared from cycloheximide-treated cells. To the contrary, the cyclin B-depleted extract of cycloheximide-treated cells was found to have the ability to inhibit the in vitro activation of p34^cdc2^/cyclin B (Fig. [4](#F4){ref-type="fig"} *B*). These findings indicated that wild-type BHK21 cells that were arrested in S phase possessed both the activator(s) and the inhibitor(s) of p34^cdc2^/cyclin B. By blocking protein synthesis, the activator(s), which was not the endogenous p34^cdc2^/cyclin B complex, was lost, but the inhibitor(s) remained. The inhibitory activity for p34^cdc2^/cyclin B of the cycloheximide-treated cell extracts may reflect either the activation of p34^cdc2^/cyclin B inhibitor(s) or the loss of balance between the inhibitor and the activator of p34^cdc2^/cyclin B.

Cdc25B Was Lost by Blocking Protein Synthesis
---------------------------------------------

To identify proteins that were required for p34^cdc2^/cyclin B activation and disappeared during treatment of cells with protein synthesis inhibitors, cultures of tsBN2 cells were synchronized in S phase at 33.5°C and then incubated at 40°C, either in the absence or presence of cycloheximide (10 μg/ml). Every hour, cells were harvested and assayed for the presence of p34^cdc2^/cyclin B activators, such as Cdc25A, B, and C, and as controls, p34^cdk2^, p34^cdc2^, and cyclin B, by immunoblotting analysis (Fig. [5](#F5){ref-type="fig"}).

While p34^cdc2^/cyclin B was activated in tsBN2 cells without cycloheximide, no activation of p34^cdc2^/cyclin B occurred in the presence of cycloheximide as previously reported ([@B42]; Fig. [5](#F5){ref-type="fig"} *A*). Parallel with the activation of p34^cdc2^/cyclin B, the molecular mass of p34^cdc2^ was shifted down to the faster-migration form, while that of Cdc25C was shifted up to the retarded-migration form (Fig. [5](#F5){ref-type="fig"} *B*), as previously reported ([@B20]; [@B22]; [@B53]; [@B16]). In tsBN2 cells treated with cycloheximide, the molecular mass of both Cdc25C and p34^cdc2^ did not change, consistent with the fact that there was no activation of p34^cdc2^/cyclin B. The amount of Cdc25A and C and p34^cdc2^ seemed to be constant during treatment with cycloheximide. However, Cdc25B became undetectable after inhibiting protein synthesis for 1 h. Loss of Cdc25B was also observed in cycloheximide-treated wild-type BHK21 cells (Fig. [6](#F6){ref-type="fig"} *A*), indicating that Cdc25B was an unstable protein in BHK21 cells.

Interestingly, even in the absence of cycloheximide, the amount of Cdc25B was gradually reduced and finally lost in parallel with the reduction in histone H1 kinase activity of p34^cdc2^/cyclin B, similar to cyclin B (Fig. [5](#F5){ref-type="fig"}, compare *A* and *B*).

Cdc25B Is an In Vitro Activator of p34^cdc2^/cyclin B
-----------------------------------------------------

To confirm that Cdc25B is an activator required for the in vitro activation of p34^cdc2^/cyclin B, Cdc25B, and as a control, Cdc25C, which is essential for p34^cdc2^/cyclin B activation induced by loss of RCC1 ([@B53]), were depleted from the cytosolic extract prepared from nontreated, wild-type BHK21 cells, using the anti-Cdc25B and Cdc25C antibodies, respectively. Depletion of Cdc25B and Cdc25C was confirmed by immunoblotting analysis (Fig. [6](#F6){ref-type="fig"} *A*). In both cases, Cdc25A remained in the extracts.

Cdc25B- and Cdc25C-depleted extracts were then incubated at 30°C for 1 h. The p34^cdc2^/cyclin B complex was activated in the Cdc25C-depleted extract, but not in the Cdc25B-depleted extract (Fig. [6](#F6){ref-type="fig"} *B*, *cdc25B* and *cdc25C*). The effect of Cdc25B depletion was further confirmed using the extracts from which p34^cdc2^/cyclin B had been depleted, in addition to Cdc25B or CdC25C. These extracts alone possessed no activity of p34^cdc2^/cyclin B. However, as shown in Fig. [6](#F6){ref-type="fig"} *C*, the cyclin B- and Cdc25C-depleted extract contained the ability to activate the p34^cdc2^/cyclin B complex of the extract prepared from cycloheximide-treated cells, whereas the cyclin B- and Cdc25B-depleted extract did not.

To further confirm the involvement of Cdc25B in the in vitro activation of p34^cdc2^/cyclin B, proteins were immunoprecipitated from the extracts of cycloheximide-treated and nontreated cells, using the anti-Cdc25B antibody and assayed for their abilities to activate the p34^cdc2^/cyclin B complex within the extract of cycloheximide-treated cells. Proteins that were immunoprecipitated from the extracts of nontreated cells activated p34^cdc2^/cyclin B, but those precipitated from cycloheximide-treated cells did not (Fig. [7](#F7){ref-type="fig"} *A*). In both cases, immunoprecipitated proteins alone had no activity of histone H1 kinase. As a control, Cdc25C was immunoprecipitated from the extract of BHK21 cells arrested either in S phase or in mitosis. While Cdc25C derived from mitotic cells had an ability to activate the p34^cdc2^/cyclin B complex within the extract of cycloheximide-treated cells, Cdc25C derived from S phase-arrested cells did not (Fig. [7](#F7){ref-type="fig"} *B*). These findings indicated that Cdc25B was an activator of the p34^cdc2^/cyclin B complex, which was lost by cycloheximide treatment.

Cdc25B Directly Activated p34^cdc2^/cyclin B
--------------------------------------------

To address the question of whether Cdc25B directly activate p34^cdc2^/cyclin B, Cdc25B was immunoprecipitated from the extract of nontreated cells, and as a control, from the extract of cycloheximide-treated cells. On the other hand, the p34^cdc2^/cyclin B complexes were immunoprecipitated using the anti-cyclin B antibody, from the extracts of cycloheximide-treated and nontreated cells. Proteins immunoprecipitated with the anti-Cdc25B antibody alone had no activity of histone H1 kinase (Fig. [8](#F8){ref-type="fig"}, *base line*). By mixing with the p34^cdc2^/cyclin B, which had no histone H1 kinase activity by itself (Fig. [8](#F8){ref-type="fig"}, *zero point*), Cdc25B of nontreated cells activated p34^cdc2^/cyclin B complexes isolated from both the extracts of nontreated and cycloheximide-treated cells, with a similar kinetics (Fig. [8](#F8){ref-type="fig"}, *A* and *B*). As a control, mock-precipitated Cdc25B from cycloheximide-treated cells had no ability to activate p34^cdc2^/cyclin B.

Compared to the p34^cdc2^/cyclin B retained within the extract, the isolated p34^cdc2^/cyclin B complexes were highly activated by Cdc25B (compare Fig. [7](#F7){ref-type="fig"} and 8). This finding may suggest that the inhibitors for p34^cdc2^/cyclin B activation retained within the extracts were removed from the p34^cdc2^/cyclin B complexes by immunoprecipitation. With these results taken together, we concluded that Cdc25B directly activated the p34^cdc2^/cyclin B complex, while we could not exclude the possibility that some proteins that were co-precipitated with p34^cdc2^/cyclin B or with Cdc25B, activated Cdc25B before the activation of p34^cdc2^/cyclin B ([@B12]). These findings also indicated that the protein modification required for the activation of p34^cdc2^/cyclin B was not lost by blocking protein synthesis.

Cdc25B Is a Short-Life Protein in Mammalian Cells
-------------------------------------------------

Our present results suggest that Cdc25B was lost in tsBN2 and wild-type BHK21 cells treated with protein synthesis inhibitor cycloheximide. Since the accumulation of truncated, abnormal proteins may enhance ubiquitin-dependent proteolysis ([@B15]), it is possible that Cdc25B, which is stable in a normal growth condition, becomes unstable by blocking protein synthesis. To address this question, Cdc25B was pulse labeled with \[^35^S\]methionine and chased in the presence of an excess amount of cold methionine in wild-type BHK21 cells that had been arrested in S phase. As shown in Fig. [9](#F9){ref-type="fig"} *A*, Cdc25B was rapidly lost even in the absence of cycloheximide. To further confirm the instability of Cdc25B, human Cdc25B (a gift of H. Okayama) was transfected into wild-type BHK21 cells, and the expressed human Cdc25B was pulse--chased in randomly growing wild-type BHK21 cells. Exogenously expressed human Cdc25B was rapidly lost with a half-life of \<30 min, similar to the endogenous Cdc25B (Fig. [9](#F9){ref-type="fig"}, *A* and *B*). In the same cultures of wild-type BHK21 cells expressing human Cdc25B, the endogenous hamster Cdc25B was lost with the kinetics similar to that of human Cdc25B (data not shown). Thus, Cdc25B was unstable in BHK21 cells, and the stability of Cdc25B was not changed by arresting cells in S phase with hydroxyurea. Even in HeLa cells, Cdc25B, but not Cdc25A and Cdc25C, was lost during treatment with cycloheximide (Fig. [9](#F9){ref-type="fig"} *C*). Taking these results together, we concluded that Cdc25B was rapidly turning over in mammalian cells.

All of p34^cdc2^ in the Extract Was Not Activated by Cdc25B
-----------------------------------------------------------

To address the question whether the observed in vitro activation of p34^cdc2^/cyclin B complex reflects a full activation of p34^cdc2^ within the extract, we added the *E. coli*-produced Cdc25C to the extract of BHK21 cells. By the addition of *E. coli*-produced Cdc25C, the histone H1 kinase activity was increased compared to the extract alone (Fig. [10](#F10){ref-type="fig"}). This finding indicated that all of p34^cdc2^ in the extract was not activated by Cdc25B. Probably, in our reaction condition, the activity of p34^cdc2^/cyclin B complexes obtained by the in vitro incubation was not enough to overcome the threshold for mitotic entrance, which is supposed to be carried out by forming a positive feedback mutual activation loop between Cdc25C and p34^cdc2^/cyclin B complexes ([@B22]; [@B16]; [@B19]). To address this issue, we added an increasing amount of p34^cdc2^/cyclin B complexes that had been activated by Cdc25B, to the extract of S phase-arrested BHK21 cells. However, the high activation of the p34^cdc2^ that was obtained by the addition of *E. coli*-produced Cdc25C, did not occur by the addition of extra p34^cdc2^/cyclin B complexes (data not shown). The similar result has been reported by [@B27] using *Xenopus* egg extract.

Over-Expression of Cdc25B Enhanced Chromatin Condensation
---------------------------------------------------------

To address whether Cdc25B is rate limiting for entry into mitosis, increasing doses of Cdc25B cDNA were introduced into wild-type BHK21 cells using lipofection. Transfected cells were synchronized at G~1~ by isoleucine deprivation and then at S phase with HU. After incubation for 15.5 h in the presence of HU, cells were stained with Hoechst 33342, and cells showing PCC were scanned with photomicroscope. There were no cells showing PCC (\<0.1%). Next we examined whether over-expressed Cdc25B can enhance chromatin condensation induced by addition of caffeine. HU-arrested cells were given 5 mM of caffeine along with 0.2 μg/ml of nocodazole and every hour, cells were scanned for cells showing PCC by photomicroscope. As shown in Fig. [11](#F11){ref-type="fig"}, the frequency of cells showing PCC was increased in a dose-dependent manner of transfected Cdc25B cDNA. When \> 6 μg/35-mm dish of Cdc25B cDNA was introduced into cells, cells rapidly died as previously reported ([@B30]). Thus, the question whether the amount of Cdc25B is rate limiting for entry into mitosis still remains to be answered. But our present finding indicates that Cdc25B enhanced chromatin condensation. Alternatively, it is possible that over-expressed Cdc25B could not stimulate cells to enter mitosis due to the tight cellular regulation of Cdc25B activity, since no cells showing PCC appeared until 2 h after caffeine addition, even in the case of a higher dose of Cdc25B cDNA.

Discussion
==========

Cdc25B Is a Short-Life Protein
------------------------------

The activation of p34^cdc2^/cyclin B occurs in the extract prepared from S phase-arrested hamster BHK21 cells without protein synthesis, but not in the extract of cells pretreated with protein synthesis inhibitor cycloheximide, which inhibits the in vivo activation of p34^cdc2^/cyclin B as well. Taking these results together, it can be deduced that S phase- arrested hamster BHK21 cells possess all the molecules required for the observed activation of p34^cdc2^/cyclin B and that either some molecules or protein modifications that are required for the activation of p34^cdc2^/cyclin B were lost by blocking protein synthesis. Since the p34^cdc2^/cyclin B complexes of cycloheximide-treated cells can be directly activated by immunoprecipitated Cdc25B, the modification of p34^cdc2^/cyclin B may not be lost. It is, therefore, rational to consider that some molecule(s) essential for the activation of p34^cdc2^/cyclin B is lost by blocking protein synthesis.

Cyclins are most important proteins for the mitotic activation of p34^cdc2^/cyclin B, and their cellular contents change depending on the cell cycle ([@B44]). In hamster BHK21 cells, cyclin B is present in S phase-arrested cells as reported ([@B42]). The amount of cyclin B, however, is not reduced by cycloheximide treatment. The other protein that is essential for the activation of p34^cdc2^/cyclin B is a family of dual-specificity phosphatase Cdc25 that perform dephosphorylation of Thr-14 and Tyr-15 ([@B6]). Among the family of Cdc25 phosphatases, we have found that Cdc25B, while Cdc25A and Cdc25C are stable, is lost by blocking protein synthesis. Indeed, the half-life of Cdc25B is \<30 min in hamster BHK21, and also in HeLa cells. In this context, Cdc25B is unique among the Cdc25 family. The finding that human Cdc25B expressed in hamster wild-type BHK21 has a short life similar to hamster Cdc25B suggests that mammalian Cdc25B possesses a character of rapid turn over. Consistent with the loss of Cdc25B by cycloheximide treatment, the immunodepletion of Cdc25B from the extract abrogates the in vitro activation of p34^cdc2^/cyclin B.

Cdc25B Functions as a Trigger for Mitosis
-----------------------------------------

Previously we have found that Cdc25C is essential for p34^cdc2^/cyclin B activation induced by the loss of RCC1 ([@B53]). However, Cdc25C is not required for the observed in vitro activation of p34^cdc2^/cyclin B. Cdc25C from mitotic cells activates p34^cdc2^/cyclin B within the extract of cycloheximide-treated cells, but Cdc25C of S phase-arrested cells does not. This finding is consistent with the previous finding that during G~2~/M transition, Cdc25C is phosphorylated and thereby activated, parallel with the activation of p34^cdc2^/cyclin B ([@B22]; [@B19]; [@B16]). In fact, the molecular mass of Cdc25C in S phase-arrested cells is not high like in mitotic cells. It has been reported that Cdc25C has a low activity of tyrosine phosphatase even in the interphase ([@B22]; [@B19]; [@B17]). We think that the discrepancy between our results and the previous ones may be due to the difference in materials. We stringently synchronized BHK21 cells into S phase by using the stepwise method; that is, first, cells were arrested in G~0~/G~1~ by isoleucine deprivation and then in S phase with HU.

In tsBN2 cells arrested in S phase, the activation of p34^cdc2^/cyclin B can be induced at 40°C, the nonpermissive temperature, and in parallel with the activation of p34^cdc2^/ cyclin B, p34^cdc2^ is dephosphorylated and Cdc25C is phosphorylated ([@B42]; [@B53]; current study), as found in *Xenopus* extract ([@B22]; [@B19]; [@B16]). Based on these observations, we assume that the premature activation of p34^cdc2^/cyclin B induced by tsBN2 mutation mimics a normal entrance of mitosis. In this context, we notice that loss of Cdc25B is coincident with loss of p34^cdc2^/cyclin B activation, both in vivo and in vitro. Interestingly, the content of Cdc25B was reduced in parallel with the activation of p34^cdc2^/cyclin B and the molecular shift of Cdc25C. These findings may suggest that Cdc25B initially activates the p34^cdc2^/cyclin B complexes, which, in turn, phosphorylate Cdc25C, forming a positive feedback, mutual activation loop between Cdc25C and p34^cdc2^/cyclin B. Consistent with the notion that Cdc25B functions as a trigger for the initiation of mitosis, the in vitro activation of p34^cdc2^/cyclin B carried out by Cdc25B is lower compared to the activation of p34^cdc2^/cyclin B that is carried out by constitutively active *E. coli*-produced Cdc25C.

To prove that Cdc25B is a "starter" for the mitotic activation of p34^cdc2^, it will be essential to show that the antibody to Cdc25B that neutralizes the enzyme activity of Cdc25B blocks the initiation of mitosis in mammalian cells.

Cellular Regulation of Cdc25B Function
--------------------------------------

While Cdc25C is activated by phosphorylation ([@B20]; [@B22], [@B24]), it is not yet clear how Cdc25B is activated. The finding that Cdc25B immunoprecipitated before the in vitro incubation activates the p34^cdc2^/cyclin B complexes that were isolated from cycloheximide-treated cells indicates that the Cdc25B of S phase-arrested BHK21 cells is active. If Cdc25B is already active in cells, there must be some regulatory system to prevent the p34^cdc2^/cyclin B from the premature activation. In this context, the in vitro spontaneous activation of p34^cdc2^/cyclin B in the cell extract suggests that the cell disruption that may mimic loss of the cellular compartment causes an activation of p34^cdc2^/cyclin B. In the interphase, therefore, we assume that the compartment mechanism that restrains an interaction between an enzyme and its substrate may play a role in the regulation of p34^cdc2^/cyclin B activation. In human HeLa cells, cyclin B1 is anchored in the cytoplasm during the interphase and enters the nucleus at the beginning of mitosis ([@B47], [@B48]). Recently, Nim1, which phosphorylates and thereby inhibits Wee1, is found to be localized in the cytoplasm, whereas Wee1 is localized in the nucleus ([@B46]; [@B29]; [@B14]; [@B62]). In both mammalian and yeast, thus, the cellular compartment of proteins seems to play a role in regulating the initiation of mitosis. In this regard, we notice that loss of RCC1, which performs GDP/GTP exchange of Ran GTPase (Bischoff and Ponstingl, 1991), induces the activation of p34^cdc2^/cyclin B ([@B42]). The Ran GTPase is essential for nucleus/cytosol exchange of macromolecules ([@B31]; [@B35]) and for nuclear processing of mRNA ([@B52]; [@B54]). Loss of RCC1 may accumulate the GDP-bound form of Ran GTPase, thereby, disturbing the Ran GTPase cycle. We are tempted to speculate, therefore, that the cellular compartment required for the cell cycle progression is regulated by the Ran GTPase.

Unstable Triggers and Stable Inhibitors for the Initiation of Mitosis
---------------------------------------------------------------------

Although we could not exclude the possibility that the other unstable proteins like Cdc25B are also required for the initiation of mitosis, our findings indicate that the activator(s) is rapidly turning over, but the inhibitor(s) is stable. In S phase-arrested BHK21 cells, the activator(s) and the inhibitor(s) for p34^cdc2^/cyclin B seem to be balanced, and thereby, cells do not enter mitosis. The instability of the p34^cdc2^/cyclin B activator(s) may reflect an adaptation of cells to stresses, including the inhibition of protein synthesis. In such circumstances, it is better for cells to remain in a less active state of p34^cdc2^/cyclin B, or otherwise cells will suffer further damage from proceeding through the cell cycle. In this context, it seems to be reasonable that the 'starter\' for the mitotic entrance is labile.

By loss of the activator(s), the presence of p34^cdc2^/cyclin B inhibitor(s) became obvious. It is also possible that the inhibitor(s) was activated by cycloheximide treatment. In mammalian cells, the inhibitory kinases for p34^cdc2^/cyclin B like Wee1 and Myt1 ([@B46]; [@B36],*b*), the phosphatase INH/PP2A ([@B3]; [@B26], [@B27]) and the stoichiometric inhibitors ([@B23]; [@B25]) have been reported to prevent the activation of p34^cdc2^/cyclin B in the interphase. The finding that the addition of p34^cdc2^/cyclin B complexes pre-activated by Cdc25B could not induce a full activation of p34^cdc2^/cyclin B in the extract, suggests that our extracts contain the inhibitory kinase of p34^cdc2^/cyclin B or the phosphatase INH/PP2A.

In summary, our results indicate that Cdc25B functions as a trigger for mitosis. Our finding that Cdc25B is an unstable trigger for the entrance of mitosis will provide a new aspect regarding the check point control. In *S. pombe*, the level of Cdc25 is regulated by ubiquitin ligase Pub1 ([@B39]). Probably it is also true in mammalian cells. The stabilization of Cdc25B, therefore, may disturb the cell cycle control at the G~2~/M transition.
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![In vivo and in vitro activation of p34^cdc2^/cyclin B in tsBN2 cells. (*A*) Cultures of tsBN2 cells synchronized in S phase with HU were incubated at 40°C in the presence of HU. Every hour, cells were harvested and lysed to prepare the total cell extract. From 10 μl (protein concentration: 3 mg/ml) of the total cell extract, the p34^cdc2^/cyclin B complexes were precipitated using p13^suc1^ beads and assayed for histone H1 kinase activities. (*B*) The total cell extracts prepared from tsBN2 cells that had been incubated at 40°C for 0 (--□--), 1 ( --♦--), 2 (--▪--), and 3 (--⋄--) h were incubated at 30°C. Every hour, 10 μl of the extracts (protein concentration: 3 mg/ml) were sampled and mixed with the reaction-stopping buffer. The p34^cdc2^/cyclin B complexes were precipitated using p13^suc1^ beads and assayed for histone H1 kinase activities. Histone H1 kinase activities shown in *A* correspond to the value at the beginning of incubation (time: 0) in *B* as shown by arrows.](JCB.32833f1){#F1}

![In vitro activation of p34^cdc2^/cyclin B in wild-type BHK21 cells. Cultures of wild-type BHK21 cells synchronized in S phase with HU were incubated in the presence (*CHX-treated*, columns *1* and *2*) or absence (*non-treated*, columns *3--6*) of cycloheximide (10 μg/ml) for 1 h and then lysed to prepare the cytosolic extracts, as described in Materials and Methods. The cytosolic extracts were incubated at 30°C in the absence (columns *1* to *4*) or presence (columns *5* and *6*) of cycloheximide (10 μg/ml). Before incubation (columns *1*, *3*, and *5*) or after incubation for 1 h (columns *2*, *4*, and *6*), 8 μl of the extracts (protein concentration: 3 mg/ml) were mixed with the reaction-stopping buffer. p34^cdc2^/ cyclin B complexes were immunoprecipitated using the anti- cyclin B antibodies and assayed for histone H1 kinase activities.](JCB.32833f2){#F2}

![Dephosphorylation of p34^cdc2^ occurs in parallel with the activation of p34^cdc2^/cyclin B. Wild-type BHK21 cells synchronized in S phase with HU were incubated in the presence (lanes *1* and *2*) or absence (lanes *3* and *4*) of cycloheximide (10 μg/ml) for 1 h and then lysed to prepare the total cell extracts. The total cell extracts were incubated at 30°C. Before incubation (lanes *1* and *3*), and after incubation for 1 h (lanes *2* and *4*), the extracts were mixed with SDS-sample buffer and boiled. Total proteins of the mixtures were electrophoresed in SDS-10% polyacrylamide gel and analyzed by immunoblotting using as a probe, anti-pTyr (*top*) and the anti-PSTAIR (*bottom*), respectively.](JCB.32833f3){#F3}

###### 

Both activator(s) and inhibitor(s) of p34^cdc2^/cyclin B are present in HU-arrested BHK21 cells. Cultures of wild-type BHK21 cells synchronized in S phase with HU were incubated in the absence (nontreated) or presence (CHX-treated) of cycloheximide (10 μg/ ml) for 1 h and then lysed to prepare the cytosolic extracts. When indicated as cyclin B-depleted, the p34^cdc2^/cyclin B complexes were immunoprecipitated using the anti-cyclin B antibody and the supernatant was used as the cyclin B-depleted extracts as described in Materials and Methods. 8 μl of the total cytosolic extracts prepared from CHX-treated cells (*A*), from nontreated cells (*B*), and as a control of the buffer (0.5× EB-1; *C*) were mixed with 0, 4, 8, 16, and 32 μl of the cyclin B-depleted extracts prepared from nontreated (--•--) or CHX-treated cells (--○--). In each case, the final volume was adjusted to 40 μl with the buffer (0.5 × EB-1). After incubation at 30°C for 1 h, the p34^cdc2^/cyclin B complexes were immunoprecipitated using the anti-cyclin B antibodies and assayed for histone H1 kinase activities.
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###### 

Cdc25B was lost by treatment with cycloheximide. A series of cultures of tsBN2 cells synchronized in S phase with HU was incubated at 40°C in the absence (nontreated) or presence (CHX-treated) of cycloheximide (10 μg/ml). Every hour, cells were harvested to prepare the total cell extracts. (*A*) p34^cdc2^/cyclin B complexes of total cell extracts prepared from nontreated (--•--) or cycloheximide-treated cells (--○--) were immunoprecipitated using the anti-cyclin B antibody and assayed for histone H1 kinase activities. (*B*) Proteins of total cell extracts prepared from nontreated (−*CHX*) and CHX-treated (+*CHX*) cells were electrophoresed in SDS-10% polyacrylamide gel and analyzed by immunoblotting using as a probe the antibodies against the proteins indicated.
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###### 

Immunodepletion of Cdc25B blocks the in vitro activation of p34^cdc2^/cyclin B. Cytosolic extracts of wild-type BHK21 cells treated (*CHX-treated*) or not treated (*non-treated*) with cycloheximide (10 μg/ml) were prepared as described in Fig. [4](#F4){ref-type="fig"}. From the extract of nontreated cells, Cdc25B or Cdc25C was immunoprecipitated using the antibodies against Cdc25B and Cdc25C, respectively, and the supernatants were used as the Cdc25B- or Cdc25C-immunodepleted extracts. (*A*) Proteins of the total and immunodepleted cytosolic extracts were electrophoresed in SDS-10% polyacrylamide gel and analyzed by immunoblotting using the antibodies against indicated proteins. Lanes *1* and *2*, total cytosolic extract of cycloheximide-treated (*CHX*) and nontreated (*non*) cells. Lanes *3* and *4*, Cdc25B- and Cdc25C-depleted extract, respectively. (*B*) Total cytosolic extracts of cycloheximide-treated cells (*CHX-treated*) and nontreated (*non-treated*) cells and the Cdc25B- or Cdc25C-depleted extracts of nontreated cells (designated as −*cdc25B* and −*cdc25C*, respectively) were incubated at 30°C. Before incubation (*open column*) and after incubation for 1 h (*shaded column*), the p34^cdc2^/cyclin B complexes were immunoprecipitated using the anti-cyclin B antibody and assayed for histone H1 kinase activities. (*C*) From the cytosolic extract of nontreated cells, cyclin B and then either Cdc25B or Cdc25C were immunodepleted using the antibodies against cyclin B, Cdc25B or Cdc25C, respectively: cyclin B-depleted (−*cyclin B*), cyclin B- and Cdc25B-depleted (−*cyclinB* and −*cdc25B*), and cyclin B- and Cdc25C-depleted (−*cyclin B* and −*cdc25C*) extracts. Total cytosolic extracts of cycloheximide-treated cells (*CHX-treated*) and the immunodepleted extracts from nontreated cells (*non-treated*) were incubated alone (*open* and *shaded column*) or after mixing with the total cytosolic extract of CHX-treated cells (*filled column*) at 30°C. Before incubation (*open column*) and after incubation for 1 h (*shaded* and *filled column*), the p34^cdc2^/cyclin B complexes were immunoprecipitated using the anti-cyclin B antibody and assayed for histone H1 kinase activities.
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![Cdc25B, but not Cdc25C, activates the p34^cdc2^/cyclin B complexes of cycloheximide-treated cells. (*A*) Cdc25B proteins were immunoprecipitated using the anti-Cdc25B antibody from 8, 24, and 48 μl of the cytosolic extracts derived from nontreated (--•--) and, as a control, CHX-treated (--○--) wild-type BHK21 cells that had been arrested in S phase. The immunoprecipitated Cdc25B prepared from the indicated volume of the cytosolic extract was then mixed with 8 μl of total cytosolic extract prepared from cycloheximide-treated cells and as a control, with 8 μl of the buffer (0.5 × EB-1; nontreated: --□--; CHX-treated: -**X**-). A final volume was adjusted to 30 μl. After incubation at 30°C for 1 h, p34^cdc2^/cyclin B was immunoprecipitated using the anti-cyclin B antibody and assayed for histone H1 kinase activities. (*B*) A series of cultures of BHK21 cells was synchronized with HU in S phase, and then half of the cultures was released from HU block and arrested in M phase, as described in Materials and Methods. The cytosolic extracts were prepared from the S phase-arrested (--○--) and the M phase-arrested cells (--•--), respectively, and then Cdc25C proteins were immunoprecipitated using the anti-Cdc25C antibody from 15, 30, and 60 μl of the S and M phase extract. The immunoprecipitated Cdc25C prepared from the indicated volume of the cytosolic extract was then mixed with 8 μl of total cytosolic extract prepared from cycloheximide-treated cells. A final volume was adjusted to 30 μl. After incubation at 30°C for 1 h, p34^cdc2^/cyclin B was immunoprecipitated using the anti-cyclin B antibody and assayed for histone H1 kinase activities.](JCB.32833f7){#F7}

![Immunoprecipitated Cdc25B equally activated p34^cdc2^/ cyclin B complexes of cycloheximide-treated and nontreated cells. From 8 μl of cytosolic extracts of nontreated (*A*) or cycloheximide-treated (*B*) wild-type BHK21 cells, p34^cdc2^/cyclin B complexes were immunoprecipitated using the anti-cyclin B antibody and then mixed with proteins immunoprecipitated with the anti-Cdc25B antibodies from 8, 24, and 48 μl of cytosolic extracts derived from cycloheximide-treated (--○--) and non-treated (--•--) wild-type BHK21 cells. As a control, proteins immunoprecipitated with the anti-Cdc25B antibodies were incubated by themselves in the buffer (0.5 × EB-1; nontreated: --□--; CHX-treated: -**X**-). A final volume was adjusted to 30 μl. After incubation at 30°C for 1 h, p34^cdc2^/cyclin B was immunoprecipitated using the anti-cyclin B antibody and assayed for histone H1 kinase activities.](JCB.32833f8){#F8}

###### 

Cdc25B is an unstable protein. (*A*) Endogenous hamster Cdc25B. Wild-type BHK21 cells were seeded at 1 × 10^6^/100-mm dish, synchronized in S phase, incubated in Met-free medium containing HU, labeled with \[^35^S\][l]{.smallcaps}-methionine, and chased as described in Materials and Methods. At the indicated times (*min*), cells were lysed and Cdc25B was immunoprecipitated and analyzed by autoradiography. Human Cdc25B expressed in hamster BHK21 cells. Wild-type BHK21 cells were seeded at 2 × 10^6^/100-mm dish. After 18 h of incubation at 33.5°C, cells were transfected with plasmid pcD2-human Cdc25B (16 μg/100-mm dish) using lipofection. After incubation in a normal medium for an additional 48 h at 33.5°C, transfected cells were incubated in Met-free medium, labeled with \[^35^S\][l]{.smallcaps}-methionine, and chased as described in Materials and Methods. At the indicated times (*min*), cells were lysed and Cdc25B was immunoprecipitated and analyzed by autoradiography. (*B*) Half-life of Cdc25B. The radioactivity of immunoprecipitated, labeled endogenous hamster (--○--) and expressed human (--•--) Cdc25B was counted by an analyzer (BAS2000; Bio Image, Ann Arbor, MI). The vertical value indicates the relative count of radioactivity (C~t~/C~0~). (*C*) Cultures of HeLa cells synchronized in S phase as described in Materials and Methods were incubated for 1 h in the presence (*CHX*) or absence (*non*) of cycloheximide (10 μg/ml) and then lysed. Total proteins of the extracts were electrophoresed in SDS-10% polyacrylamide gel and analyzed by immunoblotting using the antibodies against Cdc25A, Cdc25B, and Cdc25C.
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![Activation of p34^cdc2^ within the cytosolic extract of cycloheximide-treated and nontreated cells by *E. coli*-produced hamster Cdc25B. Cultures of BHK21 cells were synchronized with HU as described in Materials and Methods, and half of the cultures were treated with cycloheximide (10 μg/ml) for 1 h before cell disruption. 8 μl of cytosolic extracts of nontreated (--•--, --▪--) or cycloheximide-treated (--○--, --□--) cultures were incubated at 30°C for indicated time (*min*), in the presence (--▪--, --□--) or absence (--•--, --○--) of *E. coli*-produced hamster Cdc25C (final concentration 100 μg/ml). A final volume was adjusted to 30 μl. After incubation, p34^cdc2^/cyclin B was immunoprecipitated using the anti-cyclin B antibody and assayed for histone H1 kinase activities.](JCB.32833f10){#F10}

![Over-expression of Cdc25B enhances chromatin condensation induced by caffeine. Wild-type BHK21 cells were seeded at 2 × 10^5^/35-mm dish. After 23 h of incubation at 33.5°C, cells were transfected with the indicated doses of pcD2-Cdc25B DNA. After transfection, cells were synchronized at S phase by isoleucine deprivation and HU as described in Materials and Methods. After S phase arrest, cells were given caffeine (final concentration 5 mM) and nocodazole (final concentration 0.2 μg/ ml) in the presence of HU and then incubated at 37.5°C. Every 2 h cells were fixed with cold methanol and stained with Hoechst 33342. More than 1,000 cells were scored for PCC. The frequency of cells showing PCC is shown on the vertical axis. Amount of transfected DNA: --○--, 0 μg/dish ; --•--, 1 μg/dish; --□--, 2 μg/dish; --▪--, 4 μg/dish.](JCB.32833f11){#F11}
